Literature DB >> 23825738

In vitro activity of Alkanna frigida extracts in comparison with glucantime against Leishmania major.

Fariba Jafari1, Abbasali Nourian, Asghar Fazaeli, Alireza Yazdinezhad, Ali Haniloo.   

Abstract

BACKGROUND AND OBJECTIVES: Current chemotherapies of cutaneous leihmaniasis have faced to some problems and limitations; Development of new leishmanicidal drugs from different sources like herbal plants, are crucially important. The objective of the present study was evaluation of in vitro activity of Alkanna frigida extracts in comparison with glucantime against Leishmania major.
MATERIALS AND METHODS: L. major promastigotes were exposed to different concentrations of the A. frigida extracts, processed by ethyl acetate, ethanol, hexane and chloroform. The inhibitory effect, as the IC50, were calculated after 24, 48 and 72 hours by linear regression analysis values of the concentrations employed.
RESULTS: The significant inhibition was observed after 24 and 48 hours with different concentrations of compounds (p < 0.05 in all tests). All extracts had potent activity against proliferation of the promastigotes, comparing to the untreated negative control. It could compete with the glucantime efficacy in some concentrations. Ethyl acetate and ethanol extractions showed potent IC50 value, 106 µg/ml and 86 µg/ml, respectively. Hexane and chloroform extractions had poor efficacy after 24 hours; however, the efficacy increased after 48 and 72 hours.
CONCLUSION: The results indicated that the A. frigida has appropriate inhibitory effects on the growth of L. major promastigotes in vitro and can be of herbal targets for further investigation in vivo.

Entities:  

Keywords:  Alkanna frigida; In vitro activity; Leishmania major; cutaneous leishmaniasis

Year:  2013        PMID: 23825738      PMCID: PMC3696856     

Source DB:  PubMed          Journal:  Iran J Microbiol        ISSN: 2008-3289


INTRODUCTION

Leishmaniasis is one of the most significant health problems amongst a collection of neglected tropical and sub-tropical diseases. It is caused by different species of the genus Leishmania, which are transmitted by dipterans of the genera Phlebotomus in the old World and Lutzomyia in the new World. Based on the world health organization (WHO) reports in past years, approximately, 12 million individuals were estimated to be infected and 350 million people were at risk of leishmaniasis in many countries (1). Annual global incidence of cutaneous leishmaniasis, based on recently reports from endemic countries, is estimated to rate between 0.7 to 1.2 million cases (2). Leishmania major and L. tropica, the two causative agents of cutaneous leishmaniasis in Iran, have long been endemic in several definite foci, affecting tens of thousands of people (3). Emergence of the disease in additional new foci in this country have been reported in recent years (4–8). Treatment of Leishmaniasis has been a big challenge since a prolonged therapy is needed. Relapses of the infection and differential susceptibilities between taxonomically closely related species of Leishmania are also of major problems (9). Contraversial challenge is also the case for antileishmanial drugs efficacy (10) even for the same clinical type of leishmaniasis. The first choice of drugs, used for treatment of leishmaniasis, are pentavalent antimonial compounds (meglumine antimoniate/glucantime and sodium stibogluconate); while amphotericin B and pentamidine are used as the second-line chemotherapy. Despite the current application of these compounds, they are restricted by side effects to the patients, i.e. anorexia, vomiting and nausea (9). Drug resistance of the Leishmania parasites against some compounds, such as the above mentioned traditional drugs is also reported (11, 12). Several other compounds have been applied for the healing of cutaneous leishmaniasis which are reviewed by some researchers (13, 14). Although, leishmanicidal drugs originated from different sources like synthetic compounds, natural products extracted from plants and marine sources have shown different degrees of efficacy in the treatment of experimental different related leishmaniasis, so far, there is no standard therapy available. One of the reasons could be unfavorable results in animal experiments, and only a small published series of susceptibility testing. Generally, available data have shown that a wide range of plant families and species have trypanocidal and leishmanicidal activities (15–17). Natural compounds may be advantageous to the chemical products for treatment of the disease for several reasons, i.e. the side effects of chemical compounds. Alkanna is described as a genus of herbaceous plants, having around 60 species, in the family of Boraginaceae. The original Alkanna plant is a native of the Levant but is now found wild and cultivated, throughout the Europe, around the Mediterranean and the Middle East. Alkanna tinctoria grows in the south of France with antibacterial activity which is often used to improve acute inflammatory, swollen, and burned wounds (18). Alkanna compounds have revealed activity and effectiveness on the treatment of acute inflammatory lesions and severe victim burns (19). Alkanna frigida extract was also reported to have potential anti-inflammatory and anti-nociceptive effects in experimentally affected laboratory animals (20). Based on the above evidences indicating the potential remedial effects in this herbal genus, we anticipated that the species A. frigida could be a good candidate to be examined as a possible antileishmanial plant. This species is broadly distributed in North and North West of Iran and some neighboring countries like Iraq. The objective of the present study was evaluation of in vitro activity of A. frigida extracts, processed by ethyl acetate, ethanol, hexane and chloroform, in comparison with glucantime (meglumine antimoniate) as an effective (positive) control, against promastigotes of L. major. Glucantime is proven to be effective against L. major and can stop the promastigote growth in vitro.

MATERIALS AND METHODS

Alkanna frigida extraction and purification

A. frigida plant is extremely available on Hashtkhani Mountain (2700-2900 meters of altitude) in the North West of Iran and they were collected before flowering stage at the beginning of June 2011. The voucher specimen was identified and deposited at the Herbarium of Department of Pharmacognozy, Faculty of Pharmacy, Zanjan University of Medical Sciences, Iran (Voucher Number: ZUMS-1027). The plant source and the species was the same as what was previously confirmed by Dr Gholamreza Amin as referred previously (21). The plant extraction was performed based on Harborne, 1998, (22) using percolation and rota-vapor apparatuses. Briefly, the root limb parts of the A. frigida were dried in shadow at 25°C for 3 days and stored at 4°C until use. Based on the percolation method, a portion of 200gr of A. frigida root was extracted by using 200 ml of hexane, and consequently with chloroform, ethyl acetate and 80% ethanol (22). 1% DMSO in RPMI-1640 medium was used for dissolving the crude extracts. Parasite Strain and Culture: Leishmania major promastigotes (MRHO/IR175/ER) were obtained from Centre for Training and Research in Skin Diseases and Leprocy, Tehran University of Medical Sciences. They were cultivated in vitro in RMPI-1640 medium (GIBCO) containing 10% inactivated foetal bovine serum (FBS) (GIBCO) for preparation of adequate promastigotes, then incubated in a standard air atmosphere at 26°C in roux flasks.

In vitro antileishmanial activity testing

The promastigote forms of L. major were collected in the exponential phase and inoculated in the 96 well microplates to a final concentration of 3 × 106 parasites per well and kept at 26°C. The plant extracts obtained by ethanol, ethyl acetate, chloroform, and hexane, were dissolved in RPMI medium, at dosages of 62.5, 125, 250 and 500 µg/ml. All tests were done in triplicate. The effects of each compound against promastigote forms were tested at 24, 48, and 72 hours after the exposure. Live parasites were counted using a Neubauer haemocytometric chamber under a microscope. Alongside of the plant extracts, glucantime with the concentrations of 62.5, 125, 250 and 500 µg/ml was used as the effective positive control and untreated promastigote cultures were used as negative control. The inhibitory effects of the obtained compounds on the Leishmania promastigotes in comparison with those of glucantime were calculated in relation to negative control (untreated cultures) using the following formulae: PI = (PC-PT)/PC × 100 where PI is the percentage of inhibition, PC is the number of live amastigotes in the control (absence of the plant extracts) and PT is the number of amastigotes in the drug-treated culture wells. The IC50, which is the concentration required to inhibit 50% growth of promastigotes after 24 hours, was calculated by linear regression analysis; the percentages of the promastigote death versus different concentrations of the plant extracts were submitted to the Excel software, analysis of which resulted in calculation of the IC50 which is mentioned in Fig. 1.
Fig. 1

Inhibitory effects of different concentrations of Alkanna frigida extracts (µg/ml), compared to glucantime, on Leishmania major promastigotes in RPMI-1640 after 24 hrs.

Inhibitory effects of different concentrations of Alkanna frigida extracts (µg/ml), compared to glucantime, on Leishmania major promastigotes in RPMI-1640 after 24 hrs.

RESULTS

The inhibitory activities of A. frigida extracts on growth of L. major promastigotes are summarized in Table 1. Significant inhibition of parasite growth was observed after 24 and 48 hours of treatment with different concentration of compounds. Glucantime was used for the comparison as a reference drug. The results showed that the extracts had potent activity against proliferation of the promastigotes. The inhibitory effects of ethyl acetate, ethanolic, chloroform and hexane extracts at the lowest concentration (62.5 µg/ml), after 24 hours were 46%, 45%, 13% and 15%, respectively (Table 1). In these conditions, it was 28% for glucantime. Parasite count and observation under a dark field microscope, showed appropriate growth and viability of promastigotes in the negative control (RPMI-1640 with 1% DMSO, without drug); the parasite death was maximum 2%. Ethyl acetate and ethanol extracts showed potent IC50 value, 106 µg/ml and 86 µg/ml, respectively; whereas hexane and chloroform extracts had poor efficacy on growth of parasite after 24 hours (Fig. 1). In contrast, significant results have been observed after 48 and 72 hours, IC50 value for chloroform extract was 330 µg/ml and 68 µg/ml for 48 and 72 hours, respectively. In addition, hexane extract IC50 had potent activity (384 µg/ml for 48 hr) and (98 µg/ml 72 hr). IC50 value for reference drug (glucantime) was 340 µg/ml increased in efficacy and showed a significant difference in comparisons with the examined compounds. Ethanol and ethyl acetate with the concentration of 500 µg/ml inhibited 76% and 74% of parasite, while glucantime in the same concentration had 60% elimination (Table 1).
Table 1

Inhibitory effects of ethanolic, ethyl acetate, chloroform and hexane extracts of Alkanna frigida on Leishmania major promastigotes in vitro.

The percentages of inhibition

Concentration µg/mlEthyl acetateEthanolChloroformHexaneGlucantime P value Chi-squar

24h* 48h72h24h48h72 h24 h48 h72 h24 h48 h72h24h48h72h
62.54657684559751330461533482847570.00001
1255463725364792138562041553852650.00001
2506272776170873745622746604558750.00001
5007484877682964461724054686070810.00001

h (hours), indicate the post treatment times of the inhibition calculations.

Inhibitory effects of ethanolic, ethyl acetate, chloroform and hexane extracts of Alkanna frigida on Leishmania major promastigotes in vitro. h (hours), indicate the post treatment times of the inhibition calculations. By using regression model and estimation of the relative danger in comparison (Table 2), we found that by passing the time, the effects of ethanol and ethyl acetate extracts of A. frigida plant could get closer to the effects of glucantime drug (Tables 2–4). During 72 hours the relative danger of ethyl acetate extract was equal to 1.09 and that of ethanol extract was equal to 1.21 (Table 4).
Table 2

Poason regression for investigation of the antileishmanial effects of ethanolic, ethyl acetate, choloroform, and hexane extracts of Alkanna frigida plant after 24 hours.

Chemical extractsUpper BoundLower BoundZRelative dangerestimationP value (Chi-square)
Ethyl acetate0.3230.321555.6491.370.3220.00001
Ethanol0.3190.317547.8361.370.3180.00001
Chloroform-0.395-0.398-.569.7990.67-0.3970.00001
Hexane-0.515-0.518-715.3370.59-0.5170.00001
Glucantime (compared group)1.0
Table 4

Poason regression for investigation of the antileishmanial effects of ethanolic, ethyl acetate, choloroform, and hexane extracts of Alkanna frigida plant after 72 hours.

Chemical extractsUpper BoundLower BoundZRelative dangerestimationP value (Chi-square)
Ethyl acetate.196.194377.8381.2153.1950.00001
Ethanol.193.191370.5161.2116.1920.00001
Chloroform-.265-.267-457.1330.76-.2660.00001
Hexane-.265-.267-457.1330.76-.2660.00001
Glucantime (compared group)1.0
Poason regression for investigation of the antileishmanial effects of ethanolic, ethyl acetate, choloroform, and hexane extracts of Alkanna frigida plant after 24 hours. Poason regression for investigation of the antileishmanial effects of ethanolic, ethyl acetate, choloroform, and hexane extracts of Alkanna frigida plant after 48 hours. Poason regression for investigation of the antileishmanial effects of ethanolic, ethyl acetate, choloroform, and hexane extracts of Alkanna frigida plant after 72 hours.

DISCUSSION

The results showed that Alkanna frigida extracts have potent activity against proliferation of L. major promastigotes. Ethyl acetate and ethanol extracts showed the IC50 values of 106 µg/ml and 86 µg/ml, respectively. Hexane and chloroform extracts had poor efficacy after 24 hours; however, the efficacy increased after 48 and 72 hours. Although the agents of leishmaniasis are susceptible to most antileishmanial drugs in vitro, treatment may be a big challenge because of the disease relapses due to diverse susceptibility to the current chemotherapies, within the species and/or isolates of the causative Leishmania parasites. Meglumine antimoniate (glucantime) and sodium stibogluconate (pentostam) are in the first line of therapy; amphotericin B with severe side effects and insufficient improvement in many reported cases are used as the second-line chemotherapy (15). Moreover, in some severe reported cases in the literature, cutaneous leishmaniasis showed failure therapy, and consequently drug does not seem to be the optimal choice for the treatment of this type of infection. Therefore, plants can be valuable basic sources for development of new therapeutic compounds. Alkanna plants and their derivatives are among the most attractive plant derivatives that might enrich the current therapy options, due to their extremely large range of biological properties (18). Thus developing newly effective drugs on the treatment of the cutaneous leishmaniasis are extremely considered. Common treatment is using pentavalent antymonials which is often toxic and can lead to the emergence of some side effects. Since long time ago, researchers have focused on the herbal drugs. In 1976, Parpagergiou et al, showed that Alkanna tinctoria extract has antibacterial effects and also healing effect on wound (18). Also, Alkanna tincktoia extract on the wounds of burning was conducted on the rabbits and the results show that the plant extract has positive effects on the wounds of burning (23). In a study by Esfahani et al. (2012), potential anti-inflammatory and anti-nociceptive effects of ethanolic extract of Alkanna frigida in rat and mouse inoculated by carrageenan and formalin, were also reported (20). They found significant decrease in carrageenan induced inflammation using 200 and 400 mg/kg of the extract after 1 and 2h; remarkable anti-nociceptive effect was also of their findings. In our study, leishmanicidal activity of A. frigida plant on L. major promastigotes, revealed that ethyl acetate extract with a concentration of 106 µg/ml during 24 hours can inhibit 50% of promastigotes propagation. The leishmanicidal activity of ethanol extract was close to that of ethyl acetate (Table 1, Fig. 1). However, chloroform and hexane extracts showed lower efficacy in comparison with ethanol and ethyl acetate extracts. The ethyl acetate and ethanol extracts after 48 and 72 hours also showed to have the most effective leishmanicidal activity in comparison with the other two chemical extracts. The estimation of relative risk also indicated that the antileishmanial effects of these two extracts, are close and even higher than the effects of glucantime (Tables 2–4). Similarly, in a study of leishmanicidal evaluation of the Artemisia species by Imami and colleagues in 2008, the ethanol extract was also more effective than the other extracts, including chloroform and hexane extracts (24). Alcoholic extract of another plant, Calendula officinalis, on Leishmania promastigotes was more effective, comparing to its watery extracts (25). Different concentrations of the ethanol and ethyl acetate extracts in comparison with glucantime under the same conditions, exhibited higher efficacy (Table 1, Fig. 1). However, based on these data, the A. frigida extracts cannot be considered superior to glucantime and remain to be evaluated further, in terms of their toxicity effect and compound analysis. It was basically concluded that the A. frigida extracts have inhibitory effects on the L. major promastigote proliferation and the ethanol and ethyl acetate extracts have more leishmanicidal effects than those of chloroform and hexane extracts.
Table 3

Poason regression for investigation of the antileishmanial effects of ethanolic, ethyl acetate, choloroform, and hexane extracts of Alkanna frigida plant after 48 hours.

Chemical extractsUpper BoundLower BoundZRelative dangerestimationP value (Chi-square)
Ethyl acetate0.900.88186.6071.090.890.00001
Ethanol0.1930.192411.4581.210.1920.00001
Chloroform-0.163-0.165-.320.5180.84-0.1640.00001
Hexane-0.184-0.186-.360.3270.83-0.1850.00001
Glucantime (compared group)1.0
  19 in total

1.  The effect of Alkanna tinctoria Tausch on burn wound healing in rabbits.

Authors:  Z Ogurtan; F Hatipoglu; C Ceylan
Journal:  Dtsch Tierarztl Wochenschr       Date:  2002-11

Review 2.  Topical treatment modalities for old world cutaneous leishmaniasis: a review.

Authors:  R Alavi-Naini; A Fazaeli; T O'Dempsey
Journal:  Prague Med Rep       Date:  2012

3.  The changing profile of cutaneous leishmaniasis in a focus of the disease in Jahrom district, southern Iran.

Authors:  M H Davami; M H Motazedian; B Sarkari
Journal:  Ann Trop Med Parasitol       Date:  2010-07

4.  Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals.

Authors:  J El-On; G P Jacobs; E Witztum; C L Greenblatt
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

5.  Anti-inflammatory and anti-nociceptive effects of the ethanolic extracts of Alkanna frigida and Alkanna orientalis.

Authors:  H Monsef Esfahani; Z Navvab Esfahani; N Khosravi Dehaghi; A Hosseini-Sharifabad; K Tabrizian; M Parsa; Seyed Nasser Ostad
Journal:  J Nat Med       Date:  2011-11-16       Impact factor: 2.343

Review 6.  Cutaneous leishmaniasis.

Authors:  Richard Reithinger; Jean-Claude Dujardin; Hechmi Louzir; Claude Pirmez; Bruce Alexander; Simon Brooker
Journal:  Lancet Infect Dis       Date:  2007-09       Impact factor: 25.071

7.  Wound healing properties of naphthaquinone pigments from Alkanna tinctoria.

Authors:  V P Papageorgiou
Journal:  Experientia       Date:  1978-11-15

8.  Emergence of cutaneous leishmaniasis due to Leishmania major in a new focus of central Iran.

Authors:  Mohammad Motovali Emami; Mahbobeh Yazdi; Mohamadali Nilforoushzadeh
Journal:  Trans R Soc Trop Med Hyg       Date:  2009-06-03       Impact factor: 2.184

Review 9.  Leishmaniasis: current situation and new perspectives.

Authors:  P Desjeux
Journal:  Comp Immunol Microbiol Infect Dis       Date:  2004-09       Impact factor: 2.268

10.  A new epidemic focus of zoonotic cutaneous leishmaniasis in central Iran.

Authors:  Mohammad Reza Yaghoobi-Ershadi; Reza Jafari; Ahmad Ali Hanafi-Bojd
Journal:  Ann Saudi Med       Date:  2004 Mar-Apr       Impact factor: 1.526

View more
  1 in total

Review 1.  Medicinal plants with promising antileishmanial activity in Iran: a systematic review and meta-analysis.

Authors:  Masoud Soosaraei; Mahdi Fakhar; Saeed Hosseini Teshnizi; Hajar Ziaei Hezarjaribi; Elham Sadat Banimostafavi
Journal:  Ann Med Surg (Lond)       Date:  2017-07-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.